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Increased expression of cathepsins has diagnostic as well as prognostic value in several types of cancer. Here,
we demonstrate a novel magnetic resonance imaging (MRI) method, which uses poly-L-glutamate (PLG) as
an MRI probe to map cathepsin expression in vivo, in a rat brain tumor model. This noninvasive,
high-resolution and non-radioactive method exploits the differences in the CEST signals of PLG in the
native form and cathepsin mediated cleaved form. The method was validated in phantoms with known
physiological concentrations, in tumor cells and in an animal model of brain tumor along with
immunohistochemical analysis. Potential applications in tumor diagnosis and evaluation of therapeutic
response are outlined.
M
any tumors have been shown to exhibit elevated levels of proteases in incipient stages, which are thought
to play a crucial role in tumor angiogenesis, invasion andmetastasis1. Knowledge of the roles of proteases
in tumor progression will potentially guide the development of novel diagnostic tools for early detection
of tumors as well as disease modifying therapeutic strategies to combat tumors. Cathepsins, cysteine family
proteases, are lysosomal proteases involved in cellular protein degradation and are over-expressed in many
tumor cells as well as host cells associated with the tumor2,3. Out of eleven types of cathepsins, cathepsin B
(CtB) and cathespin L (CtL) are predominantly involved in protein degradation within the lysosome4.These
cathepsins have been shown to be prognostic indicators of many types of tumors5–8. The wide availability of
cathepsins on tumor cells makes them attractive targets for tumor detection as well as for studying tumor
evolution under therapy.
However, despite the tremendous significance, it is challenging to accomplish noninvasive detection of prote-
ase activity in vivo. Except for near infrared fluorescence (NIRF) optical imaging, there has been no known high
resolution, noninvasive and nonradioactivemethods to detect CtB activity in tumors in vivo9–13. In spite of its high
sensitivity, NIRF suffers frompoor depth penetration (fewmm) and cannot be translated into a three dimensional
(3D) imaging tool either in large animal models or in humans. Furthermore, it requires synthesis and evaluation
of toxicity of the injected compounds. Therefore, there is an unmet need for a noninvasive, high-resolution
imaging technique for measuring the expression of cathepsins in tumors.
Here, for the first time, we demonstrate poly-L-glutamate (PLG) as a tumor protease activated magnetic
resonance imaging (MRI) probe, which enables high resolution mapping of expression of cathepsins in tumors,
in vivo. PLG is a nontoxic polymer that can be readily injected into animal models up to several millimoles (mM)
without causing any adverse reactions13–17. This noninvasive, nonradioactive method is based on the chemical
exchange saturation transfer (CEST) between protons attached to nitrogen in amine moieties with bulk water
protons. Owing to very slow exchange rates of backbone amide protons (Fig. 1a), PLG in its native form does not
exhibit appreciable CEST under physiological conditions. However, cleavage by the lysosomal enzymes such as
cathepsins, results in individual glutamate (Glu) moieties as well as smaller Glu peptides, which readily exhibit
CEST effect from their amine protons (Fig. 1b)18. Determination of the relationship between the protease
expression and PLG degradation via CEST can establish a potential noninvasive MRI method for quantifying
tumor protease expression.
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Results and Discussion
TheCEST effect fromGlu and PLGwith and without addition of CtB
is evaluated in in vitro at frequency offset, Dv5 3 ppm downfield to
bulk water (Fig. 2a). Glu showed a strong CEST contrast due to its
exchangeable amine protons18 while no CEST contrast was observed
from PLG due to very few amine protons. But the cleavage products
of PLG showed an appreciable CEST contrast due to the exposure of
amine protons interacting with bulk water after enzymatic CtB cleav-
age (Fig. 2a).
PLG cleavage by CtB can be monitored in vitro through proton
magnetic resonance spectroscopy (1HMRS; Figs. 2 b–d). The 1HMRS
spectrum from Glu showed three distinct peaks respectively at
,2.02 ppm,,2.25 ppm and,3.66 ppm (Fig. 2b). PLG also showed
three peaks at ,2.01 ppm, ,2.28 ppm and ,4.1 ppm (Fig. 2c).
Addition of CtB splits the 2.28 ppm and 4.1 ppm peaks (Fig. 2d).
The splitting of PLG peaks denotes its cleavage by CtB.
Further, we assessed the expression of CtB in 9L tumor cells. CEST
imaging of 9L cells was performed with and without addition of PLG.
With addition of PLG, the 9L cell line showed , 20% increase in
CEST contrast compared to the cells without PLG, while there was no
appreciable CEST contrast observed from PLG alone (Figs. 3a–c).
The increased CEST contrast can be attributed to the cleavage of PLG
by the cathepsins expressed in tumor cells. Since the two cathepsins
i.e. CtB and CtL are primarily responsible for cleavage of PLG,
Western blot analysis of 9L cell lysates was performed to determine
the presence of CtB and CtL expression (Fig. 3d). Western blot
analysis showed expression of CtB both in the mature and pro form.
However, mature CtB was predominantly expressed than its pro
form. The CtL was expressed only in the pro form. This suggests that
cleavage of PLG in 9L cells is primarily due to the expression of
mature CtB.
The feasibility of mapping CtB expression in in vivowas evaluated
on a 9L rat brain gliosarcoma model (Figs. 3 e–g, Figs. 4 a–e). PLG
(160 mg/kg) was injected in these rats through the tail vein andCEST
imaging was performed up to 90 minutes with a 30 minutes time
interval. A continuous increase in CEST contrast was observed in the
tumor region due to the cleavage of PLG by protease enzyme (prim-
arily CtB) expressed in tumor. We further performed immunohisto-
chemistry of rat brain tumor tissues for CtB expression. A strong
positive expression of CtB was observed in the tumor region while
the normal appearing brain (NAB) showed negligible expression of
CtB. The same tumor region showed higher nuclear density and
mitosis reflecting increased cellular proliferation than NAB region
on hematoxylin and eosin stain (Figs. 4f–i).The graph (Fig. 4j) shows
the mean (6SD) CEST contrast from tumor (n56) as well as NAB
region (n56). A progressive increase in CEST contrast from tumor
region was observed over the period of 90 minutes, while the CEST
contrast from NAB did not change appreciably over the time course
of 90 minutes. An average of 19% increase in CEST contrast was
observed from tumor region after 90 minutes injection of PLG
(Fig. 4k).
Since PLG mediated CEST contrast directly depends on the
expression of cathepsin proteases, monitoring changes in the CEST
contrast in vivo will enable the quantitation of cathepsin expression
in different tumor types.
Conjugation of polymers to anticancer drugs is an emerging
approach for clinical development of combination therapy19. Such
studies have the potential for advancing polymer therapeutics as a
novel class of anticancer agents. These techniques primarily exploit
the degradation of polymers by the lysosomal enzymes such as
cysteine proteases, particularly CtB and CtL16,19–22. In particular,
PLG has been used as a macromolecular carrier for drug delivery16
Figure 1 | Poly L-glutamate (PLG) as a protease activated CEST contrast agent. (a). Molecular structure of PLG shows three amine protons in exchange
with the bulk water. Multiple amide protons are also present in the backbone of PLG. Due to the presence of significantly lower number of exchangeable
amine protons, the saturation transfer of these protons does not reduce bulk water signal noticeably and therefore no appreciable CEST contrast is
observed from PLG. No CEST contrast is observed from amide protons due to its slow exchange rate and saturation power and duration used in the
current study. (b). Proteolytic cleavage of PLG into monomers (i.e. glutamate) and/or smaller peptide fragments exposes fair number of exchangeable
amine protons. The exchange of saturated magnetization of these amine protons with bulk water significantly reduces the bulk water signal and results in
appreciable CEST contrast.
www.nature.com/scientificreports
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and PLG in combination with paclitaxel (PG-TXL) has advanced to
clinical trials23,24. Since the development and application of targeted
delivery of anticancer agents using PLG as the drug carrier is emer-
ging23,24, we envisage that, in the long term, the proposed CEST
imaging technology has the potential to monitor PLG conjugated
drug delivery and therapeutic response of tumors.
This is the first study to show that PLG can be used as a protease
activated MRI probe for tumor mapping in vivo and PLG degrada-
tion by cathepsins in tumors can be imaged with high resolution
MRI. We expect that the current method will have numerous appli-
cations in cancer research including differentiation of radiation nec-
rosis from tumor growth as well evaluating anti-autophagy therapies.
Figure 2 | PLG as a marker of cathepsin B (CtB) enzyme activity. (a). Anatomical proton density weighted MR image showing three different
solutions (Glu, PLG, and PLG1Ctb) in NMR tubes immersed in a PBS phantom. (b). CEST contrast map at 3 ppm downfield to the bulk water from
glutamate (Glu), PLG and PLG with CtB. Glu shows a strong CEST contrast. No CEST contrast was observed from PLG alone. After addition of CtB an
appreciable CEST contrast was observed, this is due to the cleavage of PLG in to smaller fragments by CtB. This cleavage exposes significant number of
labile –NH3
1protons, which can be easily detected usingCESTMRI. (c-e). 1HMR spectra fromphantoms containing Glu, PLG, and PLG1CtB. Spectrum
from Glu shows multiple peaks related to aliphatic protons at,2.02,,2.25and,3.66 ppm. Spectrum from PLG shows 3 peaks respectively at,2.02,
,2.28 and,4.1 ppm. The spectra are broad due to reducedmobility of PLGmolecule and hence the fine structure ismasked. Phantomwith PLG andCtB
is showing splitting of 2.28 and 4.1 ppm peaks, due to cleavage of PLG by CtB.
Figure 3 | PLG as a marker of protease enzyme expression in cancer 9L cells. (a). Cancer cells cultured without any PLG. This image shows ,22%
CEST contrast, which is due to endogenous Glu in cultured cells. (b). Same cell line (as in a) cultured in the presence of PLG (20 mg/ml) for 1 hour shows
an further elevation of ,17% of the CEST contrast over the baseline indicating that the CtB present in the tumor cells cleaved the PLG. (c). PLG
alone in saline does not show any appreciable CEST effect owing to the slow exchange of amide protons present on the PLG. (d). Western blot analysis of
tumor cell lysates shows both mature and pro form of CtB while cathepsin L (CtL) was expressed only in the pro form. The cleavage of PLG in this tumor
cell line is predominantly due to CtB. (e), (f). Baseline anatomical CEST weighted image and CEST map from a rat brain with a 9L tumor. (g). At 60
minutes post intra-venous injection of PLG (160 mg/kg), a ,32% increase in GluCEST contrast was observed in the tumor region.
www.nature.com/scientificreports
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Methods
All animal experiments were performed according to an approved University of
Pennsylvania Institutional Animal Care and Use Committee Protocol.
In vitro Study. Phantom Experiment. Solutions of 20 mg/ml PLGwere prepared with
and without addition of 0.5 mg/ml CtB enzyme (Sigma Aldrich, USA) in 10 mm
NMR tubes. In addition, 10 mM sodium glutamate solution was also prepared. These
phantoms were placed in a larger bottle containing phosphate buffered saline (PBS)
and the CEST imaging of these phantoms was performed at room temperature on a
7T whole body MRI scanner (Siemens Medical Systems, Malvern, PA, USA).
For CEST imaging a frequency selective saturation pulse followed by a segmented
radiofrequency spoiled gradient echo (GRE) readout sequence was used. The
sequence parameters were: slice thickness 5 10 mm, flip angle 5 10u, TR 5 5.6 ms,
TE 5 2.7 ms, field of view 5 100 3 100 mm2, matrix size 5 192 3 192, and one
saturation pulse and 64 segments acquired every 10 s. CEST images were collected at
peak B1rms of 3.64 mT and 1 s saturation duration for the frequencies (12.4 to
13.6 ppm and 22.4 to 23.6 ppm in 0.2 ppm steps) from bulk water resonance.
Radiofrequency field inhomogeneity (B1) and static magnetic field inhomogeneity
(B0) maps were also obtained to correct for any inhomogeneities as described
previously18.
Single voxel spectra (SVS) with point-resolved-spectroscopy (PRESS) acquisition
mode were performed from each phantom using the following parameters: voxel size
5 5 mm 3 5 mm 3 20 mm (Voxel volume 500 mL), spectral width 5 4 kHz,
number of points 5 2048, averages 5 64, TE 5 20 ms, and TR 5 3 s. Water
suppression was achieved using the variable pulse power and optimized relaxation
delays method (VAPOR).
Cell experiments. Rat 9L gliosarcoma cells were cultured in DMEM containing 10%
Fetal Bovine Serum, containing Penicillin-streptomycin. 9L cells growing in log phase
were trypsinized and used for in vitro and in vivo studies.
Ten million 9L cells were trypsinized and washed with sterile PBS and transferred
to a 0.5 ml microfuge tube. Six tubes with equal volume of 9L cells were obtained for
MR imaging. These tubes were categorized in two groups. In the first group (n53),
0.1 ml of normal saline was added, while in the 2nd group (n53) 0.1 ml of PLG
solution was added making a total concentration of 20 mg/ml. CEST imaging was
performed on a 9.4 T horizontal bore small animal MR scanner (Varian, Palo Alto,
CA). CEST imaging was performed using a custom-programmed segmented radio-
frequency GRE readout pulse sequence with a frequency selective continuous wave
saturation preparation pulse. The sequence parameters were: field of view 5 30 3
30 mm2, slice thickness 5 2 mm, flip angle 5 15 degree, TR 5 6.2 ms, TE 5 2.9 ms,
matrix size 5 128 3 128. For every 8 s one saturation pulse and 128 acquisition
segments were applied. CEST images were collected using a 1 second saturation pulse
at B1rms of 5.87 mT for multiple frequencies (12.4 to 13.6 ppm and 22.4 to
23.6 ppm in 0.2 ppm steps) from bulk water. B1 and B0 fieldmaps were also acquired
and used to correct the CEST maps as described previously18.
Western blot analysis. 9L cells were lysed in radioimmunoprecipitation assay buffer
containing complete mini proteinase inhibitor cocktail (Roche Diagnostics, city,
state, country) and protein lysate was quantitated using Pierce BCA protein assay kit
(Thermo scientific). 9L cell lysate (40 mg) was boiled in sample buffer and loaded onto
single lane of a 10% SDS-PAGE gel under reducing conditions. The separated pro-
teins were blotted onto a PVDF membrane, which was blocked with 5% non-fat dry
milk for 1 hour and then probed with rabbit anti-rat CtB polyclonal IgG (4 mg/ml;
cross reacts with human and mouse; Abcam) or rabbit anti-human Ct L monoclonal
Figure 4 | In vivo imaging of cathepsin expression by monitoring PLG cleavage mediated CEST. (a). Anatomical CEST weighted image showing the
tumor as a hyper-intense region. (b). the base line CEST contrast map from the same slice. (c–e). CEST contrast maps of the same imaging slice
respectively at 30, 60 and 90minutes following PLG administration through tail vein. Following PLG injection a continuous increase in CEST contrast up
to 90minutes was observedmainly in tumor region due to cleavage of PLG into its monomer and/or smaller peptide fragments by cathepsins expressed in
tumor. (f). (g). Immunohistochemistry of CtB from normal appearing brain (NAB) region and tumor region showing the expression of CtB (40x). NAB
region shows very few cells positive for CtB expression while the tumor cells showed strong positivity for CtB. (h). (i). Hematoxylin and eosin staining
fromNAB and tumor regions show higher cell proliferation in tumor. (j). Graph showing PLG kinetics in the tumor (n56) and NAB (n56) for a period
of 90 minutes following the injection of PLG. (k). The graph shows the mean percentage change in the CEST contrast following PLG injection. While no
appreciable change in NAB is observed, tumor shows 19% increase in CEST contrast in about 90 minutes. One way analysis of variance showed a
significant change (p 5 0.048) in CEST contrast over the time period of 90 minutes.
www.nature.com/scientificreports
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IgG (1 mg/ml; Abcam) for 1 hour, followed by detection with HRP-conjugated goat
anti-rabbit IgG (154000 dilution; Bio-Rad). The blot was stained with Amersham
ECL western blotting substrate and imaged using Fujifilm LAS3000 imager.
In vivo Study. Rat brain tumor. To develop intracranial tumors, rat gliosarcoma cells
(9L) were used. Syngeneic female Fisher rats (F344/NCR, four-six weeks old)
weighing 130–150 g were used to generate tumor-bearing rats as described
previously25. Briefly, general anesthesia was induced by isoflurane followed by
intraperitonial injection of a ketamine (91 mg kg21) and acepromazine (9.1 mg kg21)
mixture. A 10 ml suspension of 50,000 9L cells in phosphate buffered saline was
injected into the cortex at a depth of 2 mm with a Hamilton syringe and a 30-gauge
needle using a stereotactic apparatus (3 mm lateral and 3 mm posterior to the
bregma). These rats were subjected to MR imaging four weeks after implantation of
tumor cells.
RatMR imaging.MRI imaging was performed on tumor bearing rats three weeks after
9L cell implantation. Rats were transferred to a 9.4T horizontal bore small animalMR
scanner (Varian, Palo Alto, CA) and placed in a 20-mm diameter commercial
quadrature proton coil (m2m Imaging Corp., Cleveland, OH). Animals were kept
under anesthesia (1.5% isoflurane in 1 liters/min oxygen) and their body temperature
maintained with the air generated and blowing through a heater (SA Instruments,
Inc., Stony Brook, NY). Respiration and body temperature were continuously mon-
itored using a MRI compatible small animal monitoring system (SA Instruments,
Inc., Stony Brook, NY). The Institutional Animal Care and Use Committees of the
University of Pennsylvania approved experimental protocols.
CEST imaging of rat brain tumor was performed using the pulse sequence and
parameters as described in case of 9L cell line imaging except field of view 35 3
35 mm2. After baseline imaging the rats were injected with 1 ml PLG (160 mg/Kg)
solution at a rate of 0.1 ml perminute through the catheter inserted in a tail vein. After
PLG administration, CEST imaging was performed at each 30 minute time interval
for a total period of 90 minutes.
At the end of the study the rats were euthanized by CO2 asphyxiation and brain
tissue was collected for immunohistochemical studies.
Immunohistochemistry.All the excised rat brains were fixed in 10% buffered formalin
and embedded in paraffin. The whole brain specimen was blocked and 6 mm sections
were taken for immunohistochemistry analysis. The slides were deparaffinized in
Xylene (Surgipath, 03672) followed by rehydration with 100%, 95%, 70% ethanol.
Antigen retrieval was performed in the digital decloaking chamber (Biocare medical,
DC2002) by using citric acid based antigen unmasking solution (Vector laboratories,
H-3300). The sections were blocked with 4% BSA (Sigma, A-7906) and 2% goat or
horse serum in TT buffer (10 mMof Tric-HCI, 500 mMNaCI, and 0.05%Tween-20)
at room temperature for 30 minutes. Sections were then incubated with primary
antibody diluted in blocking buffer at 4uC overnight. Following washing in Tris
buffer, secondary antibody (Vector laboratories, BA-1000 or BA-9200) in blocking
buffer was added and incubated at room temperature for 45 minutes. After three
washes, the sections were incubated with Vectastain ABC reagent (Vector laborat-
ories, PK-6100) for 40 minutes at room temperature. The sections were again washed
thrice in Tris buffer and incubated with the chromogendiaminobenzidine-tetrahy-
drochloride (DAB) ((Sigma, D4293) substrate followed by counterstaining in
hematoxylin. The sections were mounted in DPX mountant. The immunostained
slides were digitized with a 403 objective using Olympus camera.
Image Processing. All image processing and data analysis were performed using
software routines written in MATLAB (version 7.5, R2007b). Acquired CEST images
were corrected for B0 and used to generate CEST contrast map using Equation [1].
CEST(%)~100|
S{ve{Szve
S{ve
 
ð1Þ
where S-ve and S1ve are the B0 corrected MR signals at 23 ppm and 13 ppm
respectively. CEST contrast was further corrected for B1 and mapped as false-colors
onto anatomical proton image. To compute the CEST contrast, region of interests
were manually drawn on tumor and NAB regions.
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